中文名称：RO-3306
  • (5Z)-5-(6-喹啉基亚甲基)-2-[(2-噻吩基甲基)氨基]-4(5H)-噻唑酮; (Z)-5-(喹啉-6-基亚甲基)-2-((噻吩-2-基甲基)氨基)噻唑-4(5H)-酮; 2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮
  • 4(5H)-Thiazolone, 5-(6-quinolinylmethylene)-2-[(2-thienylmethyl)amino]-,(5Z)-
  • RO-3306; 5-(6-Quinolinylmethylene)-2-[(2-thienylmethyl)amino]-4(5H)-thiazolone; (5Z)-5-Quinolin-6-ylmethylene-2-[(thiophen-2-ylmethyl)-amino]-thiazol-4-one; (Z)-5-(quinolin-6-ylmethylene)-2-(thiophen-2-ylmethylamino)thiazol-4(5H)-one; (5Z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethylamino)-1,3-thiazol-4-one; 2-[[(Thiophen-2-yl)methyl]amino]-5-[1-(quinolin-6-yl)meth-(Z)-ylidene]thiazol-4-one
  • 872573-93-8
  • C18H13N3OS2
  • RO-3306 872573-93-8
  • 体外研究:RO-3306抑制CDK1/cyclin B1，CDK1/cyclin A，CDK2/cyclin E，和CDK4/cyclin D活性，Ki分别为35 nM，110 nM，340 nM，和>2000 nM。HCT116，SW480，和HeLa细胞用RO-3306处理20小时导致细胞周期完全阻滞在G2/M期。HCT116和SW480的增殖被RO-3306有效阻断。RO-3306似乎在癌细胞(HCT116和SW480)中比在非致瘤性细胞(MCF 10A和MCF 12A)中具有更强的促凋亡作用。 1